Prospectively Validating TROP2 NMR and Moving ADCs Into First-Line NSCLC

This segment looks ahead to the evidence needed to establish TROP2 NMR as a clinically actionable predictive biomarker and explores how ongoing trials may reposition TROP2-directed ADCs earlier in the NSCLC treatment pathway. Dr. Santos asks what key insights are anticipated from AVANZAR and other ongoing studies evaluating TROP2 NMR. Dr. Wistuba emphasizes that the central unmet need is prospective validation, demonstrating in randomized, forward-looking trials that the QCS-derived NMR assessment meaningfully predicts benefit and can reliably guide therapy decisions. He also notes that, beyond clinical validity, the next hurdle will be operational, including ensuring the technology can be implemented globally across diverse pathology laboratories, moving from research-use-only workflows into regulated clinical diagnostic settings (e.g., CLIA laboratories in the United States).

Dr. Santos contextualizes why this matters clinically: oncology increasingly depends on predictive biomarkers to match patients to the right therapy, and a validated TROP2 NMR could help “enrich” for patients most likely to benefit from TROP2 ADCs, potentially enabling these agents to move from later-line use into the first-line setting. He describes AVANZAR as a prospective phase 3 study evaluating an AI-based computational pathology biomarker (TROP2 NMR via QCS) in a head-to-head comparison designed to be clinically meaningful (“apple to apple”). The program highlights that endpoints such as progression-free survival and overall survival can be analyzed in relation to TROP2 NMR status, providing the type of evidence needed for clinical adoption.

The experts also reference additional first-line studies, including a three-arm trial design (TROPION-Lung10) incorporating combinations with immunotherapy and novel checkpoint approaches in a PD-L1–selected population. This naturally leads into discussion of how TROP2 NMR might complement PD-L1 testing, either as a parallel upfront test or as part of future quantitative approaches to immune biomarkers.

Finally, the segment addresses implementation realities. Both experts anticipate smoother adoption in academic or high-volume centers with digital pathology infrastructure, whereas community settings may initially rely on send-out testing to centralized laboratories. Overall, the segment frames TROP2 NMR as a promising bridge between biologic insight and real-world decision-making, pending prospective confirmation and scalable deployment.